Hosted on MSN1d
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...
Dr Reddy's in pact with Shanghai Henlius Biotech for exclusive US, Europe rights for daratumumab biosimilar
HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...
Business Wire2d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
The agreement combines Dr. Reddy’s global commercial presence with Henlius’ proven capabilities in developing biosimilars for markets worldwide. Under the terms of the agreement, Henlius will ...
JD Supra2d
FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar
Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, ...
Daily1d
Dr Reddy's Labs inks pact with Henlius for commercialization of multiple myeloma injection HLX15 in US, Europe
Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...
devdiscourse2d
Dr Reddy's and Shanghai Henlius Join Forces for Cancer Breakthrough
Dr Reddy’s Laboratories has signed a license deal with Shanghai Henlius Biotech to develop and market HLX15, an investigational cancer drug. Henlius will handle development and manufacturing, ...
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...
Morningstar2d
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary ...